Startseite

PRA-TUXBDJ63-0D1MC0

Alzheimer-Erkrankung

  • M/F
  • 18 - 55 years old
  • Non-smoker
  • Healthy

Clinical trial of a new compound that is being developed for the treatment of Alzheimer’s disease

Very positive, professional and a nice location.

Emma

Participant ICON

Find out if you qualify for this trial

  • You are a healthy male or female
  • You are between 18 and 55 years old
  • You weigh more than 50 kg
  • Your Body Mass Index (BMI) is between 18.5 and 32 kg/m2
  • Non-smoker

Good to know about this trial

  • The study compound is administered via a tablet.
  • The medical sreening takes place in Groningen or Utrecht
  • With your participation you help people with Alzheimer's disease

Download the complete research overview

Wie funktioniert es

Wie funktioniert es?

Weiter lesen

Study groups

Register without obligation for the group of your preference

THE RESEARCH PHYSICIAN ABOUT THIS RESEARCH

Additional information

In this study we will compare how quickly and to what extent three different tablets of the study compound are absorbed, transported, and eliminated from the body. This will be done by looking at the amount of the study compound in the blood after intake of the different tablets. The tablets have different strengths and are manufactured in different ways. We will also investigate how safe the new compound is and how well it is tolerated when it is administered to healthy participants.

WHO CAN PARTICIPATE?

Target group

  • You are a healthy male or female.
  • You are at least 18 and no more than 55 years old.
  • You weigh at least 50 kg and your Body Mass Index (BMI) is higher than or equal to 18.5 and lower than or equal to 32.0 kg/m2. The BMI shows the relationship between body weight in kilograms and height in meters.
  • You did not smoke, vape, or use nicotine patches or sprays, and nicotine chewing gum in the 3 months prior to screening.

Note:

  • You cannot participate in the trial if you have participated in another clinical trial in the 30 days prior to the first study drug administration in this clinical trial (counting from the follow-up visit of the previous trial). This might be longer for certain trials, please contact us for more information.
  • To determine if you are suitable to participate in this trial, you will undergo a medical screening. 

As a female you can only participate if you are not pregnant, not breast feeding, and meet one of the following conditions:

  • You use contraception (for example the contraceptive pill or intra-uterine device) in combination with a condom;
  • You have passed the menopause (no periods for at least 12 months);
  • You have been sterilized or your male partner has been sterilized;
  • You are only sexually active with a partner of the same sex;
  • You are not sexually active according to your lifestyle.

As a male you can only participate if you meet one of the following conditions:

  • You use a condom in combination with an additional contraception method used by your female partner;
  • You have been sterilized and you are using a condom with your female partner;
  • Your female partner is sterilized or has passed the menopause (no periods for at least 12 months);
  • You are only sexually active with a partner of the same sex;
  • You are not sexually active according to your lifestyle.

WHAT IS THE COMPENSATION FOR THIS RESEARCH?

Compensation

You will receive a gross compensation of € 3599 for full participation in one of the cohorts.

Travel expenses will be reimbursed based on the distance traveled (€ 0.21 net per kilometer) with a minimum of € 13 and a maximum of € 176.40 (840 kilometers) per round trip, regardless of the mode of transportation.

HOW LONG DOES THIS RESEARCH TAKE?

Period of stay and research

The trial consists of 3 periods during which you will stay in the research facility in Groningen for 5 days (4 nights) per period. The follow-up visit will take place between 2 to 4 days after your last departure from the research facility.

Note: You must be available for all dates to be able to participate in this clinical trial. The location in Groningen is Van Swietenlaan 6.

Frequently asked questions

Sie dürfen höchstens 4 Mal pro Jahr an einer Studie teilnehmen. Zwischen zwei Studien müssen mindestens 30 Tage liegen. Für einige Studien gilt eine längere Wartezeit.

Während der Studie können leichte Beschwerden wie Kopfschmerzen oder Übelkeit auftreten. Dies kann durch das Medikament verursacht werden. Aber es kann zum Beispiel auch daran liegen, dass Sie für die Studie nüchtern bleiben müssen. Diese Nebenwirkungen sind unangenehm, aber glücklicherweise nicht gefährlich.

Bevor ein Medikament am Menschen erprobt werden darf, wurde es bereits umfassend in einem Labor getestet. So lässt sich gut vorhersagen, welche Nebenwirkungen eventuell bei Ihnen auftreten werden, damit Sie sich darauf einstellen können. So kommt es fast nie vor, dass Teilnehmer unter unerwarteten Nebenwirkungen leiden.

Eine Studie umfasst in der Regel fünf bis zwölf Teilnehmer. Die Gruppen werden so zusammengestellt, dass sie optimal zu den Anforderungen der Studie passen. Diese Anforderungen sind in jeder Studie beschrieben. Sehen Sie sich alle aktuellen Studien an.

ICON führt häufig Studien mit radioaktiv markierten Medikamenten durch. Damit können wir untersuchen, wie und wie schnell das Medikament im Körper aufgenommen, verarbeitet und ausgeschieden wird. Bei einer Studie mit radioaktiv markiertem Medikament ist das Risiko von Nebenwirkungen geringer als bei anderen Studien. In diesen Studien wird eine viel geringere Dosis verabreicht. Erfahren Sie mehr über Studien mit radioaktiv markierten Medikamenten.

Current trials

Participate in another study?

View all clinical trials
View all clinical trials